Shanghai Vitalgen BioPharma Co., Ltd.
Shanghai Vitalgen BioPharma Co., Ltd.
Explore linked clinical trials.12 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of VGN-R08b in Patients With Type III Gaucher's Disease | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Gaucher Disease, Type 3, Gaucher disease, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Lysosomal Storage Diseases, Nervous System, Nutritional and Metabolic Diseases, brain disorder, central nervous system disorder, hereditary disease, inborn errors of metabolism, lysosomal lipid storage disorder, lysosomal storage disease, metabolic disease, nervous system disorder, sphingolipidosis | Not yet recruiting | Phase 1 / Phase 2 | 2026-05-22 | NCT07603050 | |
| A Safety Study of Contralateral Eye Dosing of VGR-R01 in Participants With Bietti's Crystalline Dystrophy (BCD) | Bietti crystalline corneoretinal dystrophy | Not yet recruiting | Phase 1 / Phase 2 | 2026-05-14 | NCT07586306 | |
| A Study to Evaluate the Tolerability, Safety and Efficacy of VGM-R02b | glutaryl-CoA dehydrogenase deficiency | Recruiting | Phase 1 | 2026-05-13 | NCT06217861 | |
| A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 Mutations | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Not yet recruiting | Phase 1 / Phase 2 | 2026-05-01 | NCT07414290 | |
| A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Severe AADC Deficiency | aromatic L-amino acid decarboxylase deficiency | Active, not recruiting | Phase 2 / Phase 3 | 2026-04-21 | NCT06432140 | |
| A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Patients With Parkinson's Disease | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Active, not recruiting | Phase 1 / Phase 2 | 2026-03-31 | NCT06480461 | |
| VGN-Ex05e in Patients With Autism Spectrum Disorder Associated With Severe Self-Injurious and Aggressive Behaviors | autism spectrum disorder, neurodevelopmental disorder, pervasive developmental disorder, psychiatric disorder | Not yet recruiting | Early phase 1 | 2026-02-25 | NCT07433517 | |
| Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients With Bietti Crystalline Dystrophy | Bietti crystalline corneoretinal dystrophy | Active, not recruiting | Phase 3 | 2025-12-24 | NCT06699108 | |
| Safety and Tolerability of VGR-R01 for Patients With Bietti Crystalline Dystrophy | Bietti crystalline corneoretinal dystrophy | Active, not recruiting | Phase 1 | 2025-12-24 | NCT05694598 | |
| The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Early phase 1 | 2025-05-15 | NCT06849401 | |
| An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher Disease | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Gaucher disease, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Lysosomal Storage Diseases, Nervous System, Nutritional and Metabolic Diseases, brain disorder, central nervous system disorder, hereditary disease, inborn errors of metabolism, lysosomal lipid storage disorder, lysosomal storage disease, metabolic disease, nervous system disorder, sphingolipidosis | Recruiting | Early phase 1 | 2024-02-22 | NCT06272149 | |
| An Early Clinical Trial to Evaluate VGN-R09b for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency. | aromatic L-amino acid decarboxylase deficiency | Recruiting | Early phase 1 | 2023-03-13 | NCT05765981 |